Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastases

Objective Osteosarcoma is the most common primary bone sarcoma. About 50% of patients develop metastatic disease and their 5-year survival lingers at around 20%–30%. T cell checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade, but their impact remains limited i...

Full description

Saved in:
Bibliographic Details
Main Authors: Hans Gelderblom, Peter A van Veelen, Noel de Miranda, Arnoud H de Ru, Judith V M G Bovée, Dina Ruano, Marieke Ijsselsteijn, Manon van der Ploeg, Siddh van Oost, Debora M Meijer, Jessica P Roelands, I H Briaire-de Bruijn, B E van den Akker, A B Kruisselbrink, P M Wijers-Koster, S W Lam, R T N Tjokrodirijo, M A J van de Sande, M L Kuijjer
Format: Article
Language:English
Published: BMJ Publishing Group 2024-08-01
Series:BMJ Oncology
Online Access:https://bmjoncology.bmj.com/content/3/1/e000472.full
Tags: Add Tag
No Tags, Be the first to tag this record!